# SYNTHESIS AND IN VITRO ANTITUMOR ACTIVITY OF NOVEL 6-AMIDINO-**SUBSTITUTED 2-ALKYL-BISBENZOTHIAZOLES**


Livio Racané and Lucija Ptiček, Department of Applied Chemistry, Faculty of Textile Technology, University of Zagreb, Zagreb, Croatia Petra Grbčić and Sandra Kraljević Pavelić, Department of Biotechnology, Centre for high-throughput technologies, University of Rijeka, Rijeka, Croatia

## INTRODUCTION

In the field of drug discovery and development, biologically important heterocyclic molecules known as "privileged structures" play an important role as promising future drug candidates because of their versatile binding properties for different biotargets. Moreover, benzothiazoles and their derivatives have shown a wide range of biological activities such as anticancer, antimicrobial, antiviral and antioxidant. The benzothiazole nuclei is already a structural part of some drugs used in clinical applications, such as for example zopolrestat for the treatment of diabetes, riluzole for the treatment of amyotrophic lateral sclerosis, or frentizole used as an antiviral or immunosuppressive agent [1]. In continuation of our previous research in the synthesis and evaluation of antiproliferative activities of amidino-substituted 2aryl(heteroaryl)bisbenzothiazole derivatives [2-5], we present here the design, synthesis and antiproliferative activity of a series of dicationic 6-amidino-2alkylbisbenzothiazole derivatives.

#### **RESULTS AND DISCUSSION**

The synthesis and structure of dicationic 6-amidino-2-alkylbisbenzothiazole derivatives is outlined in Scheme 1. Previously, we developed robust methods for the preparation of a number of 6-amidino-2-aryl/heteroaryl-benzothiazole derivatives by condensing 5-amidino-substituted 2-aminothiophenoles (1a-1c) with carboxylic acids in polyphosphoric acid (PPA) [2, 3] and following this methodology we prepared novel 6-amidino-substituted 2-alkyl-bisbenzothiazoles (3a-3c, 4a, 4b, 5a-5c, 6a, 6b, 7a-7c, 8a and 8b) in moderate to good yields. The structures of compounds were determined by using <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy, mass spectrometry and elemental analysis. Antiproliferative activity was studied on four human tumor cell lines in vitro: CFPAC-1 (ductal pancreatic adenocarcinoma), SW620 (metastatic, colorectal adenocarcinoma), HepG2 (hepatocellular carcinoma) and HeLa (cervical carcinoma), as well as on normal fibroblasts HFF-1 (human skin fibroblasts). As a positive control, 5-fluorouracil was used. The results obtained are summarized in Table 1.



Compound	n	IC <sub>50</sub> *(mM)				
		SW620	HepG2	CFPAC-1	HeLa	HFF
<b>3</b> a	2	>100	34.75±3.13	81.30±19.06	50.10±16.75	0.58±0.09
<b>3b</b>	2	4.13±1.20	3.75±0.55	4.90±0.05	2.39±0.03	0.29±0.13
<b>3</b> c	2	>100	>100	>100	>100	6.04±1.32
<b>4</b> a	3	>100	93.78±21.50	>100	>100	4.47±1.92
<b>4b</b>	3	9.68±1.27	22.25±0.96	21.48±2.08	8.29±1.07	2.34±0.37
<b>5</b> a	4	48.71±10.86	23.92±7.00	37.56±6.04	15.57±6.77	0.02±0.01
<b>5b</b>	4	3.41±1.05	3.03±0.26	3.90±0.12	1.99±0.21	0.11±0.04
<b>5c</b>	4	98.17±7.49	13.83±1.46	78.99±6.16	5.77±1.18	3.56±2.05
<b>6</b> a	5	31.14±4.78	22.24±12.43	28.57±5.14	9.67±1.65	0.05±0.01
<b>6b</b>	5	2.50±1.04	3.38±0.59	3.98±0.33	2.40±0.88	0.03±0.01
<b>7</b> a	6	4.68±1.93	3.94±1.05	12.98±4.33	2.57±0.12	< 0.01
<b>7b</b>	6	1.14±0.93	1.81±0.51	0.94±0.06	$1.04{\pm}0.14$	< 0.01
<b>7</b> c	6	79.35±4.51	$\textbf{37.53} \pm \textbf{4.43}$	$\textbf{76.03} \pm \textbf{6.38}$	3.84±1.16	2.82±0.58
<b>8</b> a	7	4.86±1.82	3.20±1.79	6.19±1.33	1.71±0.54	< 0.01
<b>8b</b>	7	0.59±0.90	2.78±0.01	2.22±0.84	2.42±0.47	0.10±0.01
5-Fluorouracil		0.80±0.07	55.20±3.22	0.14±0.10	8.81±1.05	0.94±0.13
<sup>*</sup> IC <sub>50</sub> values are the concentrations that cause 50% inhibition of cancer cell growth.						

### CONCLUSIONS

The tested compounds exhibited moderate to strong antiproliferative activity towards tumor cell lines. Low micromolar potency (IC<sub>50</sub> < 5  $\mu$ M) of dicationic 6-imidazolinyl derivatives **3b**, **5b**, **6b**, **7b** and **8b** was observed on almost all tested cell lines, which is in agreement with our previous data on the antiproliferative activity of 6-amidino- and 6-imidazolinyl-2-arylbenzothiazole derivatives [4, 5]. Based on these results, compounds **5b** and **8b** were chosen as the leading compounds for further rationalized design of the benzothiazole skeleton.

#### REFERENCES

[1] Keri RS, Patil MR, Patil SA, Budagumpi S. (2015) A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. Eur J Med Chem, 89: 207–251.; [2] Racané L, Kraljević Pavelić S, Ratkaj I, Stepanić V, Pavelić K, Tralić-Kulenović V, et al. (2012) Synthesis and antiproliferative evaluation of some new amidino-substituted bis-benzothiazolyl-pyridines and pyrazine. Eur J Med Chem, 55: 108–116.; [3] Racané L, Pavelić SK, Nhili R, Depauw S, Paul-Constant C, Ratkaj I, et al. (2013) New anticancer active evaluation and DNA binding. Eur J Med Chem, 63: 882–891.; [4] Racané L, Ptiček L, Sedić M, Grbčić P, Kraljević Pavelić S, Bertoša B, et al. (2018) Eco-friendly synthesis, in vitro anti-proliferative evaluation, and 3D-QSAR analysis of a novel series of monocationic 2-aryl/heteroaryl-substituted 6-(2-imidazolinyl)benzothiazole mesylates. Mol Divers, 22: 723–741.; [5] Racané L, Ptiček L, Fajdetić G, Tralić-Kulenović V, Klobučar M, Kraljević Pavelić S, et al. (2020) Green synthesis and biological evaluation of 6-substituted-2-(2-hydroxy/methoxy phenyl)benzothiazole derivatives as potential antioxidant, antibacterial and antitumor agents. *Bioorg Chem*, 95: 103537.











